The SVP & Controller of Bristol Myers (NYSE: BMY) is Selling Shares

Bristol-Myers Squibb Co

Now the P/E of Bristol-Myers Squibb Company stands at 20.99. Also, Director Theodore R. Samuels II bought 12,000 shares of the firm's stock in a transaction dated Monday, February 27th. State of Alaska Department of Revenue acquired a new position in Bristol-Myers Squibb during the third quarter worth approximately $109,000. Baillie Gifford & Co. boosted its position in Bristol-Myers Squibb by 1.4% in the fourth quarter.

6 analysts rated the stock of Bristol-Myers Squibb Company (BMY) as "STRONG BUY", 4 rated as "BUY" and 11 issued a "HOLD" rating. BMY's market cap is $92.7B and the company has a P/E ratio of 21.27.

Stock is now moving with a negative distance from the 200 day simple moving average of approximately -5.18%, and has a poor year to date (YTD) performance of -3.94% which means the stock is constantly subtracting to its value from the previous fiscal year end price. The stock is down -4.55% in this year through last close, and the beta ratio has a value of 1.15. Expected growth of Bristol-Myers Squibb Company (BMY) for the next year 5 years is 14.47 percent (per annum), as compared to 5.73 percent (per annum) in the past 5 years. For the past 5 years, the company's revenue has grown 26.3%, while the company's earnings per share has grown -40.7%. Bristol-Myers Squibb had a net margin of 22.94% and a return on equity of 31.39%. The business had revenue of $5.24 billion for the quarter, compared to the consensus estimate of $5.14 billion.

EPS growth in next year is estimated to reach 9.91% while EPS growth estimate for this year is set at 184.60%. The company had Year Ago Sales of 4.39 Billion. Analysts forecast that Bristol-Myers Squibb Co will post $2.82 EPS for the current fiscal year. The difference between the estimated and actual earnings was $0 per share. The ex-dividend date of this dividend is Wednesday, April 5th. This represents a $1.56 dividend on an annualized basis and a yield of 2.77%. Bristol-Myers Squibb's payout ratio is presently 58.87%.

A number of research firms have recently commented on BMY. The company maintains price to book ratio of 1.18 industry average at 2.79.

What price should you pay for a company's shares? In this case, shares are down -1.39% from $64.73, the 52-week high touched on March 21, 2017, and are keeping their losses at 29.14% for the past 12 months. Also, there are 1 buy, 0 sell and 1 strong sell ratings, collectively assigning a 2.21 average brokerage recommendation.

When it comes to the Analysis of a Stock, Price Target plays a vital role.

Joseph Caldarella's trades have generated a -10.2% average return based on past transactions. A low ATR value correlates with a weaker trend movement. Following the completion of the sale, the executive vice president now owns 488,063 shares of the company's stock, valued at approximately $27,829,352.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Johnson & Johnson (NYSE:JNJ) shares are trading 6.74% above their 50-day moving average, and 7.97% above their 200-day moving average. Following the transaction, the director now directly owns 12,000 shares of the company's stock, valued at $681,240. This sentiment is slightly higher than the average sentiment of company insiders in this sector.

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. Its pharmaceutical products include chemically-synthesized drugs or small molecules and products produced from biological processes called biologics.



Other news